We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+32.94%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$177M
Cap. Flow
+$99.9M
Cap. Flow %
15.32%
Top 10 Hldgs %
81.14%
Holding
42
New
5
Increased
20
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91.4M
2
NTRA icon
Natera
NTRA
+$24.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$15.9M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$14.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$12.4M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$22.8M
2
BIIB icon
Biogen
BIIB
+$20M
3
UTHR icon
United Therapeutics
UTHR
+$12.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.94M
5
FOLD
Amicus Therapeutics
FOLD
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 96.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
$2.28M 0.35%
733,926
+2,405
+0.3% +$8.91K
CABA icon
27
Cabaletta Bio
CABA
$439M
$1.53M 0.23%
165,486
-362,319
-69% -$1.32M
XENE icon
28
Xenon Pharmaceuticals
XENE
$6.32B
$1.14M 0.17%
28,887
+95
+0.3% +$3.46K
CNTB
29
Connect Biopharma Holdings
CNTB
$135M
$642K 0.1%
739,649
– –
NGNE icon
30
Neurogene
NGNE
$696M
$61.5K 0.01%
6,038
+20
+0.3% +$207
GYRE icon
31
Gyre Therapeutics
GYRE
$662M
$47.7K 0.01%
12,065
+40
+0.3% +$163
AFMD
32
DELISTED
Affimed
AFMD
– –
-67,668
Closed -$1.39M
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.37B
– –
-435,117
Closed -$5.48M
BIIB icon
34
Biogen
BIIB
$29.9B
– –
-75,000
Closed -$20M
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
– –
-676,849
Closed -$7.07M
LQDA icon
36
CALL
Liquidia Corp
LQDA
$7.67B
– –
-507,700
Closed -$13K
RLMD icon
37
PUT
Relmada Therapeutics
RLMD
$544M
– –
-300,000
Closed -$803K
SNY icon
38
Sanofi
SNY
$104B
– –
-600,000
Closed -$22.8M
TCDA
39
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-260,000
Closed -$338K
TCDA
40
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-97,600
Closed -$122K
AKUS
41
DELISTED
Akouos Inc
AKUS
– –
-718,394
Closed -$4.86M
GBT
42
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-131,220
Closed -$8.94M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Kynam Capital Management held 42 positions worth $652M, up 37% from $475M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Kynam Capital Management deployed $99.9M of net new capital in Q4 2022, opening 5 new positions and adding to 20 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,100,000 shares worth $125M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $12.9M trimmed.

  • Kynam Capital Management's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,100,000 shares worth $125M.
  • Kynam Capital Management added most to Natera in Q4 2022, an estimated $24.1M increase.
  • Kynam Capital Management's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $12.9M.
  • Kynam Capital Management fully exited Sanofi in Q4 2022, selling an estimated $22.8M.
  • Kynam Capital Management's ten largest holdings make up 81% of its $652M portfolio in Q4 2022.
  • Kynam Capital Management opened 5 new positions and closed 11 in Q4 2022.
  • Kynam Capital Management's portfolio value rose 37% quarter-over-quarter to $652M.

Based on Kynam Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.